Boost to AEterna Zentaris's filing plans for first-in-class anticancer
This article was originally published in Scrip
Executive Summary
The EMA has informed AEterna Zentaris that the ongoing Phase III study of its lead anticancer, perifosine, in advanced colorectal cancer, along with safety data generated in other clinical studies, will be enough to file the drug.